Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED-initiated buprenorphine for adolescents with OUD
NCT04737603Phase 2Withdrawn
- Sponsor
- University of California, Davis
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of buprenorphine in opioid use disorder (OUD), sponsored by University of California, Davis. Primary endpoints: Number of participants with treatment engagement at 30 days, Mean number of days of self-reported opioid use at 30 days and 1 more. Planned start Jul 2025; status: withdrawn.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04737603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737603.